Alosetron Tablet
NDC Package 70756-702-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer),had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, andnot responded adequately to conventional therapy.Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort,frequent bowel urgency or fecal incontinence,disability or restriction of daily activities due to IBS.Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable.   Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men. This formulation utilizes a tablet delivery system. Marketed by Lifestar Pharma Llc, this product is identified by NDC 70756-702 and is authorized under FDA application ANDA213614.

Identification & Billing

NDC Package Code
70756-702-30
Package Description
30 TABLET in 1 BOTTLE
Product Code
70756-702
11-Digit Billing Format
70756070230
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Alosetron
Non-Proprietary Name
Alosetron
Substance Name
Alosetron Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ALOSETRON HYDROCHLORIDE .5 mg/1
Pharmacologic Class
Usage Information
Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer),had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, andnot responded adequately to conventional therapy.Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort,frequent bowel urgency or fecal incontinence,disability or restriction of daily activities due to IBS.Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable.   Clinical studies have not been performed to adequately confirm the benefits of alosetron tablets in men.

Regulatory & Marketing

Labeler Name
Lifestar Pharma Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA213614
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-14-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70756-702-30 identifies a specific commercial package of 30 tablet in 1 bottle of Alosetron, a human prescription drug labeled by Lifestar Pharma Llc. This tablet is formulated for oral use and contains alosetron hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lifestar Pharma Llc on September 14, 2020. The current certification is valid through December 31, 2026.

How is this Lifestar Pharma Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70756070230. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70756-702-30
11-Digit CMS (5-4-2)
70756-0702-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.